niacinamide has been researched along with Carcinoma, Ovarian Epithelial in 3 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinoma, Ovarian Epithelial: A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 6.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 6.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 2.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)." | 2.79 | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. ( Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 2.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwandt, A | 1 |
| von Gruenigen, VE | 1 |
| Wenham, RM | 1 |
| Frasure, H | 1 |
| Eaton, S | 1 |
| Fusco, N | 1 |
| Fu, P | 1 |
| Wright, JJ | 1 |
| Dowlati, A | 1 |
| Waggoner, S | 1 |
| Hainsworth, JD | 1 |
| Thompson, DS | 1 |
| Bismayer, JA | 1 |
| Gian, VG | 1 |
| Merritt, WM | 1 |
| Whorf, RC | 1 |
| Finney, LH | 1 |
| Dudley, BS | 1 |
| Bodnar, L | 1 |
| Górnas, M | 1 |
| Szczylik, C | 1 |
3 trials available for niacinamide and Carcinoma, Ovarian Epithelial